As with other metallo-β-lactamases, NDM is capable of hydrolyzing nearly all β-lactams, including carbapenems, and the search for the proper antimicrobials is challenging.
Samuel L. Aitken, PharmD, MPH, BCIDP
Advertisement
Aitken is a clinical pharmacist specialist in Infectious Diseases at Michigan Medicine with a practice focused primarily on immunocompromised hosts. He is a co-author on both editions of the IDSA guidance documents on the treatment of infections caused by gram-negative bacteria.
Articles by Samuel L. Aitken, PharmD, MPH, BCIDP
The 2019 Strategic Plan of the Infectious Diseases Society of America lays the groundwork for understanding prescribing practices.
Novel β-lactam/β-lactamase inhibitor combinations and cefiderocol may play a part in the treatment of infections caused by Stenotrophomonas maltophilia, Achromobacter xylosoxidans, and Burkholderia cepacia complex.
Advertisement
Latest Updated Articles
NDM-Producing E coli Harboring PBP Insert Variants Emerges as New ThreatPublished: August 28th 2024 | Updated:
- Evaluating the Role of New Beta-Lactam Agents for Uncommon Pathogens
Published: October 14th 2019 | Updated:
